Most Read

In Neuville sur Saône in eastern France, Sanofi will build its Evolutive Vaccine Facility (EVF) with an investment of €490m over a five-year period. The vaccine production site

The approval of Zepzelca is for treating metastatic small cell lung cancer in adults whose disease has progressed on or after platinum-based chemotherapy. The alkylating drug, which is

The phase 3 randomised, double-blind and placebo-controlled study will assess the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licenced from Incyte, in hospitalised adults with Covid-19.

Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH

Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify predictive biomarkers of response from Janssen’s VEGA study, a

The results, which were presented as a short oral presentation, included preliminary safety and efficacy data from an ongoing multicenter, open-label, dose-escalation study, which aims to determine the

In this population, VALEDIA significantly reduced fasting and post-prandial blood glucose levels, the two main risk factors for type 2 diabetes and the primary and secondary endpoints of

The progression of otilimab (previously GSK3196165) into phase III follows the results of the phase II BAROQUE study which were announced in October 2018. Dr Hal Barron, Chief

A1AT deficiency is a genetic disorder that can cause liver disease in children and adults, leading to complications such as weight loss, fatigue, jaundice and life-threatening conditions such